6-氯哒嗪-3-羧酸 | 5096-73-1

• 物质功能分类: 医药中间体 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-氯哒嗪-3-羧酸
• 中文别名: 6-氯哒嗪-3-羧基酸；3-氯哒嗪-6-甲酸；6-氯哒嗪-3-甲酸
• 英文名称: 6-chloro-pyridazine-3-carboxylic acid
• 英文别名: 3-chloropyridazine-6-carboxylic acid；6-chloropyridazine-3-carboxylic Acid
• CAS: 5096-73-1
• 化学式: C₅H₃ClN₂O₂
• mdl: MFCD00160464
• 分子量: 158.544
• InChiKey: HHGZQZULOHYEOH-UHFFFAOYSA-N

物化性质

• 熔点：
  146 °C
• 沸点：
  429.0±25.0 °C(Predicted)
• 密度：
  1.579±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloropyridazine-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloropyridazine-3-carboxylic acid
CAS number: 5096-73-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3ClN2O2
Molecular weight: 158.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

性质

6-氯哒嗪-3-羧酸在常温常压下为白色晶体粉末状。

用途

6-氯哒嗪-3-羧酸可用作医药化学与农药的小分子中间体。主要围绕其羧基进行合成转化，羧基可以不受哒嗪分子中两个氮原子的影响，参与酯化反应、还原反应和酰氯化反应。

合成方法

将155.6 mmol的3-氯-6-甲基哒嗪溶解于140 mL浓硫酸中，加入55.40 g细粉状重铬酸钾，在搅拌下缓慢滴加，并小心控制温度不超过50°C。反应完成后，在50°C继续搅拌4小时。

随后将得到的深绿色粘稠液体冷却，然后小心地加入碎冰。使用乙酸乙酯（6次，每次400 mL）萃取反应混合物，分离有机层并合并提取液。用无水硫酸钠干燥混合物，过滤去除固体硫酸钠，真空浓缩除去溶剂，即可得到目标产物——淡红色的6-氯哒嗪-3-羧酸，产率为106.6 mmol，收率约为69%。


反应信息

• 作为反应物：
  描述：

  6-氯哒嗪-3-羧酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 反应 22.0h， 生成 6-氯哒嗪-3-甲酸甲酯
  参考文献：
  名称：

  CXCR7 ANTAGONISTS

  摘要：

  提供具有化学式I的化合物，或其药用可接受的盐、水合物或N-氧化物，并且这些化合物可用于与CXCR7结合，治疗部分或完全依赖于CXCR7活性的疾病。因此，根据本发明的进一步方面，提供含有上述化合物之一或多个的组合物与药用可接受的赋形剂混合物。

  公开号：

  US20140154179A1
• 作为产物：
  描述：

  6-氯哒嗪-3-甲酸甲酯 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以75%的产率得到6-氯哒嗪-3-羧酸
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  [FR] COMPOSÉS ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DU RÉCEPTEUR DES ANDROGÈNES

  摘要：

  这项披露涉及化合物、其制备以及在需要的受试者中治疗前列腺癌，包括转移性和/或去势抵抗性前列腺癌中使用这些化合物的用途。

  公开号：

  WO2021127443A1

文献信息

• [EN] N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF<br/>[FR] N-CYCLOPROPYL-N-PIPÉRIDINYL-AMIDES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014019967A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds of general formula (I), wherein R1, LP, HetAr1, (Het)Ar2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式（I）的化合物，其中R1、LP、HetAr1、（Het）Ar2和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• [EN] OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] COMPOSÉS OXADIAZOLE, INHIBITEURS DE LA PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012027322A1

  公开（公告）日：2012-03-01

  The present invention relates to compound of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药用可接受盐，其中R1-R5如本文所定义。该发明还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• [EN] FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE<br/>[FR] COMPOSÉS DE FLAVONE POUR LE TRAITEMENT ET LA PRÉVENTION D'UNE MALADIE CAUSÉE PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020053249A1

  公开（公告）日：2020-03-19

  The present invention provides flavone derivatives having the general formula (I) which are useful for the treatment of Hepatitis B Virus infection (HBV). The compounds act as cccDNA (covalently closed circular DMA) inhibitors.

  本发明提供了具有通用公式(I)的黄酮衍生物，用于治疗乙型肝炎病毒感染（HBV）。这些化合物作为cccDNA（共价闭合环状DNA）抑制剂发挥作用。